Ralliant (NYSE:RAL) Hits New 1-Year High – Here’s Why

Shares of Ralliant Corporation (NYSE:RAL) reached a new 52-week high on Tuesday . The company traded as high as $64.04 and last traded at $63.96, with a volume of 59398 shares. The stock had previously closed at $61.03.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Truist Financial reissued a “buy” rating and set a $68.00 target price (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Citigroup boosted their price target on Ralliant from $51.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Oppenheimer boosted their price target on Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, May 13th. Vertical Research downgraded Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price target for the company. in a research note on Wednesday, May 27th. Finally, Evercore began coverage on Ralliant in a research note on Tuesday. They issued an “outperform” rating and a $80.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $67.30.

Ralliant Price Performance

The company has a 50 day moving average of $51.16 and a 200-day moving average of $49.32. The firm has a market capitalization of $6.86 billion and a P/E ratio of -5.59. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last released its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The firm had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, sell-side analysts predict that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, June 8th. Ralliant’s dividend payout ratio is presently -1.83%.

Institutional Trading of Ralliant

Institutional investors have recently modified their holdings of the stock. Danske Bank A S bought a new stake in shares of Ralliant during the 4th quarter valued at $25,000. Allworth Financial LP lifted its position in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after acquiring an additional 293 shares during the period. V Square Quantitative Management LLC bought a new stake in shares of Ralliant during the 4th quarter valued at $26,000. Palisade Asset Management LLC bought a new stake in shares of Ralliant during the 3rd quarter valued at $26,000. Finally, Rothschild Investment LLC lifted its position in shares of Ralliant by 98.1% during the 4th quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after acquiring an additional 303 shares during the period.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.